Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort.
Squillace N, Galli L, Bandera A, Castagna A, Madeddu G, Caramello P, Antinori A, Cattelan A, Maggiolo F, Cingolani A, Gori A, Monforte AD; ICONA Foundation Study Group. Squillace N, et al. Among authors: monforte ad. Medicine (Baltimore). 2016 Sep;95(36):e4434. doi: 10.1097/MD.0000000000004434. Medicine (Baltimore). 2016. PMID: 27603338 Free PMC article.
Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
Mussini C, Pezzotti P, Antinori A, Borghi V, Monforte Ad, Govoni A, De Luca A, Ammassari A, Mongiardo N, Cerri MC, Bedini A, Beltrami C, Ursitti MA, Bini T, Cossarizza A, Esposito R; Changes in Opportunistic Prophylaxis (CIOP) Study Group. Mussini C, et al. Among authors: monforte ad. Clin Infect Dis. 2003 Mar 1;36(5):645-51. doi: 10.1086/367659. Epub 2003 Feb 12. Clin Infect Dis. 2003. PMID: 12594647 Clinical Trial.
Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.
Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, Narciso P, Melzi S, De Luca A, Monforte AD, Antinori A; Adherence Italian Cohort Naive Antiretrovirals (AdICONA) Study Group; Adherence Spallanzani (AdeSpall) Study Group. Trotta MP, et al. Among authors: monforte ad. AIDS. 2003 May 2;17(7):1099-102. doi: 10.1097/00002030-200305020-00026. AIDS. 2003. PMID: 12700467
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
Svicher V, Ceccherini-Silberstein F, Erba F, Santoro M, Gori C, Bellocchi MC, Giannella S, Trotta MP, Monforte Ad, Antinori A, Perno CF. Svicher V, et al. Among authors: monforte ad. Antimicrob Agents Chemother. 2005 May;49(5):2015-25. doi: 10.1128/AAC.49.5.2015-2025.2005. Antimicrob Agents Chemother. 2005. PMID: 15855527 Free PMC article.
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group. Antonucci G, et al. Among authors: monforte ad. Clin Infect Dis. 2005 Jun 15;40(12):e101-9. doi: 10.1086/430445. Epub 2005 May 5. Clin Infect Dis. 2005. PMID: 15909251
261 results